This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
ESOGIA was a randomized phase 3 parallel-group trial evaluating treatment allocation strategies for subjects over 70 years of age with stage IV non-small-cell lung cancer.
| Feature | ESOGIA |
|---|---|
| Condition | Non Small-cell Lung Cancer |
| Population | Subjects over 70 years of age with stage IV non-small-cell lung cancer |
| Design | Randomized, parallel, open-label |
| Enrollment | 490 |
| Lead sponsor | Rennes University Hospital |
| Interventions | Dual-agent therapy or docetaxel alone or best supportive care (procedure) |
2. Clinical Question
Population
Subjects over 70 years of age with stage IV non-small-cell lung cancer.
Intervention
An optimized strategy allocating the same treatments.
Comparator
A classical strategy of treatment allocation.
Primary question
Whether the treatment allocation strategy affected time to failure.
3. Trial Design
Randomize
490 subjects
Allocation
Two strategies
Treatment
Same treatments
Follow-up
Failure assessment
Analysis
Primary endpoint
4. Endpoints
| Endpoint | Definition | Time frame |
|---|---|---|
| Time to failure | Defined from the date of inclusion to the date of documented progression, death of any cause, trial exit for toxicity considered unacceptable by the patient or investigator, or withdrawal of consent | Date of documented progression up to 6 months |
5. Planned Analysis
The ClinicalTrials.gov record identifies time to failure as the primary endpoint. For a time-to-event endpoint, statistical analysis would typically evaluate the distribution of time until the defined failure event using methods that account for censoring and differing follow-up times between randomized groups.
6. Statistical Methodology
Time-to-event analysis
Time to failure is a survival-type endpoint because the outcome is measured as the time from inclusion until the occurrence of a defined event. These analyses commonly account for participants who have not yet experienced failure at the end of observation through censoring.
Survival methods describe how event risk accumulates over time rather than only comparing event proportions at a single time point.
Randomized comparison
Because ESOGIA used randomized allocation, the treatment strategies can be compared while preserving the balance created by randomization. The registry describes allocation as randomized and the design model as parallel.
7. Statistical Methods Explained
Why is time to failure analyzed as a time-to-event endpoint?
A time-to-event approach uses both whether an event occurred and when it occurred. This is important when participants have different follow-up durations.
What does censoring mean?
Censoring occurs when the exact event time is not observed during follow-up. Proper survival methods allow these observations to contribute information up to the available follow-up time.
Why does randomization matter?
Randomization helps create comparable groups at baseline, allowing differences observed after treatment allocation to be interpreted within the randomized comparison framework.
Why is the endpoint definition important?
The ESOGIA endpoint combines documented progression, death, unacceptable toxicity-related trial exit, and withdrawal of consent. The statistical interpretation depends on exactly which events are counted as failures.
Why are published estimates needed?
Effect estimates, confidence intervals, and statistical tests require reported trial results. The registry does not provide posted statistical analyses for this trial.
8. Limitations
- No posted results: The ClinicalTrials.gov record does not report statistical analyses or outcome estimates.
- Endpoint complexity: Time to failure combines multiple possible events, so interpretation depends on the precise endpoint definition.
- Open-label design: The registry describes masking as none, meaning treatment assignment was not blinded.
- Generalizability: The enrolled population was limited to subjects over 70 years of age with stage IV non-small-cell lung cancer.
9. Why This Trial Matters Statistically
| Concept | How it appears in ESOGIA |
|---|---|
| Randomization | Randomized allocation of treatment strategies |
| Parallel design | Two concurrent trial arms |
| Time-to-event analysis | Primary endpoint measured from inclusion to failure |
| Composite endpoint interpretation | Failure includes progression, death, toxicity-related exit, or withdrawal of consent |
| Open-label design | No masking reported |
10. Sources
- ClinicalTrials.gov: ESOGIA (NCT01257139)
- Publication: PubMed record